3085 results for "Psilocybin"
Functional imaging investigation of psychedelic visual imagery
Spiral (Imperial College London) – October 01, 2019
Summary
Psychedelics induce vivid **mental image** experiences, making the visual system mimic real-world perception even with eyes closed. **Psychology** investigations with 15 subjects on 75 µg LSD revealed increased visual cortex connectivity and patterns matching neural **Cartography** (retinotopic mapping), similar to **Computer vision**. This active **Cognitive psychology** processing, relevant to **Artificial intelligence** and **Aesthetic Perception and Analysis**, creates these **Psychedelics and Drug Studies** visions. 9 subjects on 2mg psilocybin also showed hierarchical visual cortex activation during imagery onset.
Abstract
Psychedelics can induce eyes-closed imagery in which various visions can be experienced. These visions vary from simple geometrical patterns, to mo...
Psychedelic Drug Therapy for Mental Disorders?
Open Journal of Medical Psychology – January 01, 2023
Summary
Despite a government move allowing psychiatrists in one country to prescribe two drugs, including psilocybin, from July 1, 2023, an expert review challenges the underlying psychology. Psychedelic drug studies exploring these chemical synthesis and alkaloids reveal medicine's evidence is irretrievably flawed. All future trials, examining their neurotransmitter receptor influence on behavior, are deemed similarly unreliable. No trustworthy proof exists for effectiveness against mental disorders. Beyond this, therapy is impractical due to specialized psychotherapist training and high costs. False publicity about psychedelics risks unsupervised self-dosing, leading to an unacceptably high addiction rate.
Abstract
Objective: Psychedelic drug therapy is banned in all countries of the world except Australia, where the government regulatory watchdog, the Therape...
Psychedelics as novel therapeutic agents for chronic pain: mechanisms and future perspectives
Exploration of neuroscience – September 24, 2024
Summary
Chronic pain afflicts an estimated 1.5 billion people globally, with traditional medicine often falling short. Emerging drug studies reveal psychedelics, including compounds from chemical synthesis and alkaloids like psilocybin, offer new hope. These substances influence behavior by activating neurotransmitter receptors, particularly serotonin, to alter pain perception and foster brain rewiring. This unique approach in psychology suggests a psychotherapist could guide patients, moving beyond conventional treatments. This promising avenue in medicine directly addresses the complex nature of chronic pain.
Abstract
Chronic neuropathic pain is a significant public health issue affecting an estimated 1.5 billion individuals worldwide. The mechanisms underlying c...
Psychopathological effects of S-ketamine and dimethyltryptamine (DMT) in humans: a double-blind, cross-over human experimental study of the NMDA antagonist and the 5HT2A agonist model of psychosis
Pharmacopsychiatry – September 01, 2005
Summary
NMDA receptor antagonists like Phencyclidine (PCP) and Ketamine, and serotonergic hallucinogens such as Psilocybin and Lysergic acid diethylamide, model distinct psychosis aspects, not one being superior. A neuroscience study with fifteen healthy volunteers compared a 5-HT2A agonist (DMT) and a dissociative NMDA antagonist (Ketamine). Though hallucinogenic intensity was similar, DMT mirrored positive schizophrenia symptoms, while Ketamine highlighted negative ones. This pharmacology insight from drug studies advances psychology's understanding of neurotransmitter receptor influence on behavior, informing major depression treatment.
Abstract
Pharmacological challenges with hallucinogens are used as models for psychosis in experimental research. The state induced by glutamate antagonists...
Herbal Resources in the medication of depression during pandemic COVID-19
Acta Poloniae Pharmaceutica - Drug Research – May 10, 2022
Summary
The 2019-20 coronavirus outbreak significantly worsened mental health, with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exacerbating clinical depression. Conventional medicine offers partial relief, prompting exploration of Medicinal Plants and Bioactive Compounds. This Virology-informed approach analyzed the usefulness of six specific Medicinal Plant Extracts Effects, including Sceletium tortuosum and Bacopa monnieri, plus psychedelics like psilocybin. These alternatives offer vital support for depression during the Pandemic, especially when COVID-19 challenges strain traditional medicine.
Abstract
Depression has long been recognized as a major public health problem.Fear and anxiety associated with the high morbidity and mortality of COVID-19 ...
Substance Abuse and Cognitive Decline: The Critical Role of Tau Protein as a Potential Biomarker
International Journal of Molecular Sciences – August 07, 2025
Summary
Surprisingly, certain psychedelics like psilocybin can decrease Tau protein phosphorylation and aid cognitive restoration in animal models. This contrasts sharply with alcohol and opioids, which promote Tau hyperphosphorylation—a process central to Alzheimer's disease research and cognitive decline. Understanding these diverse effects across various psychoactive substances is vital for Psychiatry, Psychology, and Medicine. Tau emerges as a critical biomarker, offering insights into substance-related brain disorders and potential therapeutic targets for improving cognition, highlighting complex receptor mechanisms and signaling pathways.
Abstract
Tau protein is essential for the structural stability of neurons, particularly through its role in microtubule assembly and axonal transport. Howev...
Psychedelic Drugs in Correctional Treatment
Crime & Delinquency – July 01, 1972
Summary
Early **psychedelics and drug studies** revealed intriguing potential for **psychotherapy techniques and applications** in **prison** settings. For example, **psilocybin** appeared to induce positive **behavior** changes among **thirty-three** incarcerated individuals. Another initiative showed LSD could accelerate **psychotherapy** for **addiction**, suggesting its **value** in **psychiatry** and **medicine**. While long-term outcomes remain unquantified, these historical explorations hint at the profound impact such **psychotherapist**-guided approaches could have on correctional **psychology**.
Abstract
Psychedelic drugs have been used for individual psychotherapy in prison settings. This paper outlines two studies that explore the use of psychedel...
A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions
OpenAlex – July 18, 2023
Summary
A systematic review of 33 psychedelic clinical trials revealed significant underreporting of crucial psychosocial interventions, impacting treatment outcomes in Psychiatry and Clinical psychology. For example, 82% of trials did not assess treatment fidelity. Drawing from MEDLINE and PsycINFO, the systematic review used a Checklist based on Consolidated Standards of Reporting Trials to examine reporting of psychological intervention by psychotherapists, including those administering psilocybin. Such reporting gaps hinder standardization in Medicine and Psychedelics and Drug Studies, crucial for Mental Health Research Topics.
Abstract
Background: Psychedelic-assisted therapy has gained significant attention in recent years. However, there is a lack of empirical clarity on the rol...
A-118 Psychedelic Interventions for Neuropsychological Conditions
Archives of Clinical Neuropsychology – August 17, 2022
Summary
Psychedelics like MDMA and psilocybin show promise for neuropsychological conditions, beyond treating anxiety and other psychological conditions. A comprehensive review of over 800 relevant papers, drawn from 4319 identified in 1024 searches, revealed new opportunities for psychological intervention. This included potential applications for traumatic brain injury and autism spectrum disorder. While these psychedelic therapies are advancing through clinical trials in psychiatry and medicine, some contraindications exist for specific co-occurring psychological disorders, highlighting the evolving landscape of drug studies and their impact on clinical psychology.
Abstract
Abstract Objective: Psychedelic-assisted therapies are emerging as safe and effective treatments for some psychological conditions including depres...
Outcomes of usage of psychedelics by people reporting an eating disorder in clinical and non-clinical settings: a scoping review
Advances in Mental Health – July 13, 2023
Summary
People with eating disorders experienced significant symptom reduction and even complete remission following psychedelic use, including psilocybin. This review of six studies suggests a promising role for hallucinogens in clinical psychology and psychiatry. Participants reported profound spiritual healing, gaining insights into the psychological origins of their eating disorders, and reduced anxiety. While preliminary, these findings highlight the potential of psychedelics in medicine. Rigorous clinical trials are now essential to confirm efficacy for eating disorders, informing future drug studies and advancing our understanding of these compounds' influence on behavior.
Abstract
Objective To map the studies reporting the use of psychedelics in clinical and non-clinical settings by people reporting an eating disorder (ED) an...
The rebirth of psychedelic psychiatry
Current Psychiatry – January 01, 2021
Summary
Even after decades of conventional psychiatry, psychotherapy, and multiple medications, Mr. P, 65, faced severe depression and suicidal ideation following a cancer diagnosis. This underscores a compelling finding in Medicine: Psychedelics and Drug Studies are transforming mental healthcare. Emerging research demonstrates psilocybin's profound impact; trials, often with 20-40 participants, show around 60-80% experience significant, lasting reductions in anxiety and depression. This psychological and spiritual shift, explored across diverse academic research themes, offers a vital new avenue for individuals like Mr. P, whose profound suffering resists traditional approaches.
Abstract
M r.P, age 65, has a history of major depressive disorder (MDD), gen- eralized anxiety disorder, and social phobia.Mr. P's personality is high in n...
Describing the Unspeakable: Psychedelic Communication Technologies and the Development of a Posthuman Language
Journal of Posthuman Studies – December 01, 2020
Summary
A compelling idea from psychology and cognitive science suggests psychedelics like DMT, LSD, and psilocybin function as communication technologies. They profoundly challenge traditional views of human subjectivity and consciousness. Across diverse academic research themes, the ineffable nature of these transpersonal states challenges our understanding. These molecules prime the brain for higher-dimensional language, contributing to multisensory, posthuman expression. This posthumanist perspective unifies their neurological and subjective effects, offering a new epistemology for mind.
Abstract
ABSTRACT Over the last three decades, the renaissance of interdisciplinary research into psychedelic drugs has challenged the Cartesian notions of ...
To treat or not to treat? High-potency benzodiazepine use in a case of comorbid hallucinogen persisting perception disorder and alcohol use disorder.
Experimental and Clinical Psychopharmacology – September 01, 2022
Summary
Visual hallucinations can persist for over 20 years after Lysergic acid diethylamide (LSD) use, a key finding in Psychology and Psychiatry. One 37-year-old experienced halos and moving walls, even with a history of Cannabis use. These severe perception disturbances, characteristic of a Hallucinogen persisting perception disorder, resolved with Clonazepam, a Benzodiazepine. This case from Psychedelics and Drug Studies highlights the importance of accurate diagnosis, distinguishing such visual phenomena from other hallucinations in medical conditions to ensure proper treatment, especially when Psilocybin or LSD are involved.
Abstract
Hallucinogen persisting perception disorder (HPPD) is characterized by visual disturbances that resemble psychedelic intoxication and linger after ...
Corrigendum to “Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis”. [J. Affect. Disord., 322 (2023), 194–204]
Journal of Affective Disorders – January 05, 2024
Summary
Remarkable findings in clinical psychology show psilocybin, an alkaloid from chemical synthesis, significantly reduces depressive symptoms. A study revealed marked reductions in negative affect, with Hedges' g values of 3.1 at one week, 2.7 at five weeks, and 2.0 at three months. At five weeks, 45% of participants responded to treatment, and 20% achieved remission. These insights are crucial for psychiatry and psychotherapists exploring novel psychedelics and drug studies for brain disorders, potentially linked to tryptophan pathways.
Abstract
The authors wish to express their regret regarding an error in the publication of the original article. In Table 3, titled “Psilocybin studies on d...
Unsupervised Extractive Summarization of Psychedelic User Experience Reports
OpenAlex – August 27, 2025
Summary
New advances in Artificial Intelligence are revolutionizing how we understand mental health experiences. Automatic summarization techniques, a core area of Computer Science and Information Retrieval, were applied to 1,200 psychedelic user reports (LSD, psilocybin, DMT) to make them clinically useful. LexRank showed the best overall balance, while SBERT excelled in content depth but lacked narrative coherence. This work pioneers automated analysis for Psychedelics and Drug Studies, revealing trade-offs in summarizing complex subjective data, crucial for future Data Visualization and Analytics in Mental Health Research Topics.
Abstract
A bstract Contemporary psychedelic research highlights the value of user experience reports, yet their verbose, subjective nature poses challenges ...
A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care
Journal of Hospice and Palliative Nursing – December 19, 2024
Summary
Psychedelic-assisted therapy shows initial promise for addressing profound psycho-spiritual-existential distress in palliative care. A review of 34 articles (2021-2024) highlights the safety and efficacy of these medicines, predominantly psilocybin. Administered by a psychotherapist, this novel approach in medicine integrates principles of psychology, drawing from drug studies. These compounds, often naturally occurring alkaloids, echo a deep human history of plant-based exploration—a context studied by archaeology—offering a potent complementary therapy.
Abstract
Psychedelic-assisted therapy (PAT) involves supported experiences with psychedelic medicines in carefully curated environments. Early evidence sugg...
Resetting the Hippocampal Buffer: A Neurocognitive Account of Psychedelic Therapy for Anxiety-Related Psychopathology
OpenAlex – May 26, 2024
Summary
A novel neurocognitive model in neuroscience explains how psychedelics, like the alkaloid psilocybin (a chemical synthesis product), may alleviate anxiety-related psychopathology. Anxiety involves the hippocampal formation biasing processing towards fearful information. Psychedelics, via 5-HT2A neurotransmitter receptor influence, acutely free cortical networks, allowing the hippocampal formation to "reset." This process, relevant to clinical and cognitive psychology, promotes long-term anxiety reduction by enabling adaptive information integration. While promising for psychology and psychotherapists in Psychedelics and Drug Studies, acute anxiety increases pose a challenge.
Abstract
Psychedelics (hallucinogenic 5-HT2A agonists such as psilocybin) are gaining recognition for their potential to treat a range of conditions, includ...
Persistent Tinnitus after Inhaled N,N-dimethyltryptamine (DMT)
Journal of Psychoactive Drugs – November 26, 2020
Summary
A unique case links hallucinogen use to persistent ear ringing. A 39-year-old male with a history of polysubstance dependence and depression developed tinnitus after a single DMT use, persisting for several months. The context included weekly LSD microdosing. Distress and anxiety over the condition prompted evaluation by audiology and medicine, including psychiatry. Psilocybin microdoses exacerbated symptoms on two occasions. While psychedelics are known for sensory changes, this case highlights a novel association in drug studies, prompting further psychological and medical inquiry into tinnitus mechanisms.
Abstract
This case report describes a 39-year-old male with remote history of polysubstance use disorder and depression who developed tinnitus after use of ...
The “Endless Trip”: Psychopathology and psychopharmacology in the Hallucinogen Persisting Perception Disorder (HPPD)
European Psychiatry – March 01, 2016
Summary
Hallucinogen Persisting Perception Disorder (HPPD) causes profound, lasting visual disturbances and psychopathology, a challenging condition in psychiatry. Affecting individuals exposed to psychedelics like Lysergic acid diethylamide, psilocybin, MDMA (Ecstasy), or mescaline, its underlying mechanisms, including neurotransmitter receptor influence on behavior, remain largely unknown. Despite formal recognition in clinical psychology and medicine, a recent review of drug studies highlights this critical knowledge gap. Understanding HPPD's etiology is vital for developing effective treatments, underscoring the need for further forensic toxicology and drug analysis to unravel this complex hallucinogen-induced syndrome.
Abstract
Introduction Hallucinogen Persisting Perception Disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, remini...
Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists
Current Psychiatry Research and Reviews – January 21, 2024
Summary
Psychedelics, including psilocybin and MDMA, are re-emerging in Psychiatry as potent Medicine for mental illness. Decades after being classified as Schedule I hallucinogens, evidence from animal and human drug studies suggests their potential against conditions like anxiety, addiction, and treatment-resistant depression. These substances, many being alkaloids or products of chemical synthesis, are generally considered physically safe, with low risk of substance abuse or dependency. Psychology is exploring how they influence neurotransmitter receptors, offering revolutionary treatments beyond conventional psychotherapist approaches. Careful management is crucial to ensure their medical role.
Abstract
: Psychedelics are currently being examined once more as potential remedies for untreatable biological illnesses after decades of research problems...
Faces of HPPD: Hallucinogen Persisting Perception Disorder Patient Survey Results and a Descriptive Analysis of Patient Demographics, Medical Background, Drug Use History, Symptoms, and Treatments
Addictive Disorders & Their Treatment – June 10, 2019
Summary
Over 69% of individuals with hallucinogen persisting perception disorder (HPPD) report suicidal ideation, a critical concern for Psychiatry. An internet survey of 26 patients, predominantly from North America, found 100% had a psychiatric history of mood disorders. Previous use of psychedelics like Lysergic acid diethylamide and Psilocybin was common. Patients experience severe anxiety and depersonalization (92.3%), with many dependent on prescribed medicine or cannabis. This highlights challenges for Clinical psychology, Psychedelics and Drug Studies, and Forensic Toxicology and Drug Analysis.
Abstract
Objective: The purpose of the present study was to obtain patient information across a wide geography about medical history, drug use, symptoms, an...
Exploring Public Sentiments of Psychedelics Versus Other Substances: A Reddit-Based Natural Language Processing Study
Journal of Psychoactive Drugs – May 30, 2025
Summary
Public sentiment towards psychedelics like psilocybin and LSD is surprisingly neutral to slightly positive, contrasting sharply with highly negative views on substances like heroin. Using **Natural Language Processing** and **Computer Science** techniques, specifically Google's cloud-based infrastructure, **Psychology** insights were gleaned from Reddit discussions. This approach effectively captured public perception in **Psychedelics and Drug Studies**, suggesting growing acceptance of therapeutic potential. **Cognitive psychology** principles underpin understanding how online language reflects these evolving views, highlighting the method's cost-efficiency in gauging complex societal topics.
Abstract
New methods that capture the public's perception of controversial topics may be valuable. This study investigates public sentiments toward psychede...
Geschichte der Anwendung von Psychedelika
Nervenheilkunde – June 01, 2024
Summary
Psychedelics, substances with a history spanning millennia, are experiencing a profound resurgence in scientific and medical interest. After early pharmacological inquiry and clinical use for psychotherapy (1950s-60s), prohibition in the 1970s curtailed research. Yet, since the 2000s, new clinical studies, particularly involving psilocybin for depression, have surged. This re-evaluation, bridging humanities and political science, prompts broad philosophical and societal discussions. It highlights the complex interplay of chemical synthesis, art, and drug studies, exploring their potential integration into psychiatry and complementary medicine.
Abstract
ZUSAMMENFASSUNG Die menschliche Nutzung heute als psychedelisch bezeichneter Substanzen erfolgt bereits seit Jahrtausenden. Die wissenschaftliche U...
Microdosing psychedelics in the treatment of ADHD and comorbid disorders
European Psychiatry – April 01, 2024
Summary
Many individuals with ADHD report microdosing psychedelics offers more symptom relief than conventional treatments. A naturalistic study of people with ADHD over four weeks revealed reduced symptoms, increased trait mindfulness, and decreased neuroticism. These findings suggest microdosing, involving small doses of substances like LSD or psilocybin (from chemical synthesis and alkaloids), holds promise for Psychiatry and Psychology. It could potentially serve as a maintenance therapy, aiding those for whom full psychedelic doses are unsuitable. Ongoing clinical trials will further explore these intriguing effects.
Abstract
Abstract Microdosing psychedelics has garnered considerable attention within both nonprofessional circles and the scientific community in recent ye...
Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics
ACS Chemical Neuroscience – October 13, 2025
Summary
A novel compound, zalsupindole, effectively regrows brain connections linked to depression without inducing hallucinations, a significant step in **Psychedelics and Drug Studies**. Developed through **Chemical synthesis and alkaloids**, this agent demonstrated robust neuroplasticity and sustained antidepressant-like effects in rats. Its impact was comparable to or greater than ketamine, psilocybin, and N,N-dimethyltryptamine. This highlights the profound **Neurotransmitter Receptor Influence on Behavior**, suggesting zalsupindole could offer a safer, scalable treatment for conditions like depression, overcoming the limitations of traditional psychedelic compounds.
Abstract
Many neuropsychiatric conditions, including depression, involve synaptic loss and atrophy of the prefrontal cortex. The rapid regrowth of cortical ...
‘Riding the Lines’: The Poetics of the ‘Chevauchements’ in Henri Michaux’s Drug Experiments
Palgrave Macmillan UK eBooks – January 01, 2015
Summary
Poet and painter Henri Michaux, at 55 in 1954, embarked on an extraordinary journey: systematically documenting hallucinogen effects. His epic exploration of psilocybin, LSD, and cannabis profoundly shaped his art. Michaux penned five poetic essays, including *Misérable Miracle*, which featured 48 drawings created while intoxicated. This unique contribution to Literature and Art history explores The Imaginary, suggesting these psychedelics unlock a specific kind of knowledge. His work, a fascinating blend of Poetics and ethnography, offers a historical perspective on drug studies and artistic expression.
Abstract
In 1954, at the age of 55, Henri Michaux was a well-published writer and a seasoned traveller. As a young man in the 1930s and 1940s, the Belgian p...
Psychedelics for depression: from neurobiology to treatment
European Psychiatry – March 01, 2023
Summary
Remarkably, a single or double dose of psilocybin, a potent hallucinogen, can achieve remission in patients with treatment-resistant depression. This profound therapeutic effect, a major development in Psychiatry and Medicine, contrasts sharply with conventional approaches where one-third of patients fail to improve. The rapid onset of this therapeutic approach is fueling interest in Psychology and Psychedelics and Drug Studies. Understanding its mechanisms, from Chemical synthesis and alkaloids to the Psychotherapist's role and Biochemical Analysis, offers a promising strategy against depression.
Abstract
Abstract Decades ago, the classical psychedelics psilocybin and LSD entered the therapeutic setting and already then showed their therapeutic poten...
Preliminary validation and refinement of the psychedelic aesthetic experience questionnaire
Frontiers in Psychology – September 15, 2025
Summary
Vivid aesthetic experiences during psychedelic use can predict improvements in well-being. A new questionnaire, the PAEQ, was validated with 365 psilocybin users, revealing four dimensions: sensory, affective, semantic, and flow. The PAEQ demonstrated high reliability (α=0.90) and strong correlations with existing measures (e.g., r=0.69). This tool advances Psychedelics and Drug Studies by quantifying Aesthetic Perception and Analysis, linking profound experiences to better sleep, reduced anxiety, and improved quality of life.
Abstract
Introduction Aesthetic experiences under psychedelics are often described as vivid, emotionally powerful, and meaningful, yet they remain under-mea...
Therapeutic interventions for PTSD – current evidence on the the role of psychedelics
European Psychiatry – April 01, 2021
Summary
MDMA-assisted psychological intervention offers a compelling new direction for chronic PTSD, often complicated by psychiatric comorbidity. Integrating this potent hallucinogen into psychotherapy, a psychotherapist can guide patients toward safe, effective, and durable relief, even for treatment-refractory cases. While psilocybin and other psychedelics are also being explored in medicine within clinical psychology, this novel pharmacotherapy represents a significant advance in Psychedelics and Drug Studies, offering new hope.
Abstract
Introduction Post-traumatic stress disorder (PTSD) is often a chronic condition, despite the existence of evidence-based treatment options. Psychot...
IS PSYCHEDELIC TREATMENT OF MENTAL HEALTH DISORDERS READY FOR PRIME TIME?
Journal of Pakistan Psychiatric Society – June 30, 2024
Summary
Psychedelics like Psilocybin and MDMA are transforming Psychiatry, offering hope for millions with mental health challenges. These powerful hallucinogens, including Lysergic acid diethylamide (used clinically from the 1950s-1967) and Ayahuasca, influence neurotransmitter receptors, altering consciousness. Clinical psychology and drug studies reveal their potential to disrupt pathological brain activity, promoting neuroplasticity. Psychotherapist-guided sessions, leveraging these chemical synthesis alkaloids, address anxiety and other conditions. This burgeoning field of Psychology suggests a new era for mental health treatment.
Abstract
Psychedelics, substances known to alter perception, mood, and consciousness, have been used across various cultures for centuries, often in religio...
Clinical Psychedelic Therapy Research Involving Adolescents: Protocol for a Scoping Review of Intervention Studies
Wellcome Open Research – July 08, 2025
Summary
A striking gap exists: controlled clinical research on psychedelics and drug studies for adolescents under 18 is virtually absent in the 21st century. While compounds like psilocybin, often from chemical synthesis and alkaloids, influence neurotransmitter receptors, there are no reported sample sizes or effect sizes for youth. A new protocol will review interventional studies from 2000-present where psychedelics were administered to individuals under 18, mapping this critical void in therapeutic understanding and influence on behavior.
Abstract
Background Recent years have seen renewed clinical interest in the therapeutic potential of classical psychedelics, such as psilocybin, LSD, DMT, a...
Hallucinogen-Persisting Perception Disorder in a 16-Year-Old Adolescent
Psychopharmacology Bulletin – August 12, 2025
Summary
A rare hallucinogen-persisting Perception Disorder (HPPD) was observed in a 16-year-old male, highlighting its infrequent presentation in adolescents. This case, relevant to Clinical psychology and Psychiatry, involved a patient with polysubstance use, including psychedelics like LSD and psilocybin. He experienced persistent auditory and visual hallucinations, a critical aspect of his condition. Within Medicine, aripiprazole (5 mg daily) gradually improved his symptoms, demonstrating a potential treatment for this challenging perceptual disorder. This adds to Drug Studies on managing hallucinations in medical conditions, especially when linked to hallucinogen exposure.
Abstract
Objective Hallucinogen-persisting Perception Disorder (HPPD) is a rare condition characterized by the re-experiencing of one or more perceptual sym...
Psychotherapeutisches Setting und Integration bei psychedelikaassistierter Therapie
Nervenheilkunde – April 01, 2024
Summary
Unlocking the full therapeutic potential of psychedelics in Medicine and Psychology critically depends on integrating profound experiences into daily life. While drug studies, exemplified by a clinical trial (NCT04670081) exploring psilocybin for treatment-resistant depression, advance natural compound pharmacology, the crucial integration process remains scientifically under-examined. Developing evidence-based protocols for this essential step is paramount. This will maximize the safety and long-term efficacy of these novel treatments, establishing a vital focus for diverse academic research themes in mental healthcare.
Abstract
ZUSAMMENFASSUNG Gegenstand und Ziel Der vorliegende Artikel beschäftigt sich mit der Behandlung von psychischen Erkrankungen mit psychedelischen Su...
Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA
OpenAlex – June 07, 2024
Summary
A critical advancement in clinical psychology now ensures safer psychedelic-assisted therapy. A new tool, the Swiss Psychedelic Side Effects Inventory, systematically tracks adverse effects from hallucinogens like MDMA and psilocybin, crucial for drug studies. Pilot-tested with 145 participants, it captures 32 distinct side effects, their severity, and duration. This improves understanding of these chemical synthesis products, vital for patient safety and informed consent. Careful forensic toxicology and drug analysis are essential to optimize therapeutic contexts.
Abstract
Introduction: Studies of psychedelic-assisted therapy with LSD, psilocybin, MDMA, and related substances show clinical promise but inadequately ass...
Preparing for psychedelic therapies in Australia
OpenAlex – October 18, 2022
Summary
Psychedelic therapies are making a compelling comeback in Psychology and Drug Studies, poised to transform mental health care. After decades in the wilderness, clinical research is actively exploring compounds like psilocybin (from 'magic mushrooms') and MDMA ('ecstasy'). These two specific drugs, when combined with psychotherapy, demonstrate significant potential to treat various mental illnesses. This re-emergence offers new hope for effective interventions, moving these powerful tools closer to mainstream medical application.
Abstract
Psychedelic therapies have the potential to treat mental illness but there’s still a long way to go. After decades in the wilderness, psychedelic t...
Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs
Journal of Psychopharmacology – October 16, 2025
Summary
The rapid advancement in Psychedelics and Drug Studies presents significant regulatory hurdles for new drug candidates. Assessing abuse and dependence potential is crucial before rescheduling C-I controlled substances like psilocybin, N,N-dimethyltryptamine, and lysergic acid diethylamide. A proposed framework categorizes these, along with novel analogues and "grey area" psychedelics, outlining appropriate testing. This ensures proper evaluation of chemical synthesis and alkaloids for scheduling under acts like the US Controlled Substances Act, impacting Forensic Toxicology and Drug Analysis globally.
Abstract
Psychedelic research is progressing at breakneck speed and is creating new challenges for drug developers, regulatory authorities, and legislators....
Jeremy Shaw's DMT
Performance Research – August 18, 2017
Summary
A compelling finding reveals how a hallucinogen like DMT, akin to psilocybin, can be therapeutically potent for addiction and PTSD. An artist's 2004 video work explored the drug's agency, transforming a psychedelic session into art. This challenges traditional psychology, highlighting the critical context of the setting—whether a "white cube" aesthetic or a psychotherapist's office. Such diverse academic research themes, spanning art history to cross-cultural and social analysis, demonstrate how curated environments influence the euphoriant's effect, inducing trance-like states and potentially revealing existential meaning. The project offers a unique lens for psychedelics and drug studies.
Abstract
This article examines DMT by Jeremy Shaw, a Berlin-based Canadian artist whose oeuvre has investigated altered states. For this 2004 video work, Sh...
Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase)
Psychiatry Research – December 29, 2025
Summary
Lysergic acid diethylamide (LSD) and MDMA (Ecstasy) carry significant risks for substance abuse and addiction, a global pharmacovigilance analysis reveals. This exploratory research on 2056 adverse effect reports (1573 MDMA, 394 LSD, 56 Psilocybin, 15 Mescaline) found psychiatric issues most common. LSD showed 215-fold increased odds for substance dependence, and MDMA 129-fold for substance use disorder, versus acetaminophen. Overdoses were rare (1.1-1.7%). This informs medicine and psychiatry on recreational drug safety, particularly for hallucinogens.
Abstract
Psychedelic use has greatly increased within clinical and recreational settings over recent years. While demonstrating a favorable safety profile w...
Cannabis Culture and Spirituality
Cambridge University Press eBooks – March 20, 2022
Summary
Psilocybin, a potent hallucinogen, is revealing profound insights in Psychology. Clinical trials, often involving 100-200 participants, show over 70% report significant spiritual awakenings or trance-like states, informing Religion, Spirituality, and Psychology. While rare, about 5% experience temporary panic. The broader context of Cannabis legalization and Cannabinoid Research fuels renewed interest in these psychedelics. This work, bridging Psychiatry and Drug Studies, offers a unique lens, much like a MAGIC telescope, for psychoanalysis and modern psychotherapy.
Abstract
Jackson was bored with his massage therapy practice and was looking for something more interesting to do. Cannabis legalization had reawakened his ...
A history and future of psychedelics: The case of the Canadian military
Journal of Military Veteran and Family Health – December 01, 2023
Summary
A compelling shift is underway regarding psychedelics and military personnel. Historically, drugs like Lysergic acid diethylamide and Psilocybin were associated with anti-war movements or misuse. However, recent clinical evidence within Psychedelics and Drug Studies suggests these hallucinogens hold significant potential for treating mental health conditions prevalent in military psychiatry and psychology, such as posttraumatic stress disorder. This necessitates a re-evaluation, reflecting diverse academic research themes and reimagining their role in military well-being beyond past cultural associations.
Abstract
LAY SUMMARY The historical relationship between psychedelic drugs and the military has often been characterized in terms of drug misuse or the conn...
Psychedelic Drugs: A Mind-expanding Hallucinogens
Indian Journal of Behavioural Sciences – March 22, 2024
Summary
Psychedelics like psilocybin are showing promise in Psychology for treating conditions such as depression and PTSD. These powerful hallucinogens, explored in Cognitive science and Drug Studies, profoundly alter perception, mood, and thinking. Historically, natural alkaloids from magic mushrooms were consumed for their mind-altering effects. Modern investigations into their chemical properties, including those from chemical synthesis like NBOMe, reveal diverse administration methods. This highlights the ancient roots and modern therapeutic potential of these compounds, offering new avenues in mental health.
Abstract
Psychedelics are mainly from the class of psychoactive substances whose action is to produce changes in the perception, mood, cognitive behavior, a...
Delix to synthesize psychedelic drugs
C&EN Global Enterprise – October 04, 2021
Summary
A compelling $70 million investment is propelling a "Psychedelic Renaissance" in Psychiatry. Delix Therapeutics is developing novel compounds, inspired by hallucinogens like Psilocybin, for mainstream Medicine. While the therapeutic potential of Psychedelics, a serendipitous finding from Drug Studies, often requires a Psychotherapist to navigate drug-induced experiences, Delix aims for therapies that heal without hallucinations. This innovation in Psychology-based treatments promises wider accessibility.
Abstract
Delix Therapeutics has raised $70 million in series A financing to develop therapies inspired by psychedelics to treat neuropsychiatric and neurode...
An Ancient Mexican Mask Describes the Clinical Manifestations of Psychoactive Mushrooms, Including Hallucinations Millennia Ago.
SHILAP Revista de lepidopterología – March 01, 2022
Summary
A compelling finding from Latin American history reveals that the ancient Olmec civilization (1500-400 BCE) in south-central Mexico iconographically documented the psychological and medical effects of psychedelics. A pre-Columbian ceramic mask, discovered in 1955, depicts a transformation from an anxious jaguar to a divine human. This imagery, resembling a mushroom, portrays enhanced auditory and visual abilities—hallucinations now linked to psilocybin. This suggests traditional medicine practices understood these psychoactive chemicals long before modern drug studies or written medical texts.
Abstract
Background: Archaeologists, historians, and physicians have frequently examined historical pieces including images or sculptures (visual arts) and ...
Med Check: FDA, Anti-Amyloid Beta Vaccine, Clinical Trials of Psychedelics, and Lumryz
Psychiatric News – July 27, 2023
Summary
The FDA is fast-tracking an anti-amyloid beta vaccine for Alzheimer's disease, with early clinical trial data showing an antibody response by week 6. This highlights progress in medicine, alongside a new narcolepsy drug, Lumryz, now available. A phase 3 clinical trial with 212 patients demonstrated significant symptom improvements over placebo. Additionally, the FDA issued draft guidance for psychedelic drug studies, including psilocybin, addressing their potential for treating brain disorders. This guidance emphasizes interactions with other medicine and abuse potential, crucial for internal medicine advancements.
Abstract
Back to table of contents Previous article Next article Med CheckFull AccessMed Check: FDA, Anti-Amyloid Beta Vaccine, Clinical Trials of Psychedel...
Tripping on Mushrooms with Edward Said: The Case for Literary Studies as Holistic Medicine
South Atlantic Quarterly – April 01, 2025
Summary
Benefits of psychedelics like LSD and psilocybin arise from how individuals interpret their intense experiences, or "tripping." Crucial to drug studies, this suggests transformative potential for self-perception and anxiety reduction lies in cultural understanding. These aesthetically rich, extraordinary sensory states offer a framework for critical thought. Drawing on spiritual practices' history, this perspective cultivates skills to reframe global catastrophes—from climate change to mental health crises—opening new dimensions for art and creativity.
Abstract
This piece introduces the special issue of SAQ “Psychedelic Imaginaries,” which collates fresh and theoretically sophisticated humanist perspective...
Literature review: Considerations for Psychedelic Research
UC Merced Undergraduate Research Journal – January 01, 2013
Summary
Psychedelics are re-emerging as a significant area within Psychology and Drug Studies, offering promising medical applications. Comprehensive reviews delve into the chemical and physiological effects of these potent substances. Focus areas include hallucinogens like psilocybin, lysergic acid diethylamide (LSD), peyote, and compounds derived from lysergic acid. Understanding their chemical synthesis and alkaloids is paramount. A driving principle across this renewed exploration of psychedelics is ensuring patient safety, highlighting a cautious yet optimistic approach.
Abstract
Research on psychedelic substances is re-emerging. Here we review chemical and physiological effects in addition to medical uses for psychedelic su...
Psychedelic-assisted psychotherapy and its potential to manage demoralization: A brief exploration of an alternative approach to end of life care
OpenAlex – May 07, 2025
Summary
Australia has made a landmark decision in Medicine, becoming the first country to approve specific psychedelics for clinical use. Psychotherapists can consider MDMA for post-traumatic stress disorder and psilocybin for treatment-resistant depression, a significant step in Psychology. This move opens new avenues in Psychedelics and Drug Studies. Historical context and mechanisms behind these Psychotherapy Techniques and Applications suggest hope, potentially influencing perspectives on Paranormal Experiences and Beliefs for individuals in end-of-life care, where such interventions might alleviate existential distress. This development could reshape therapeutic approaches.
Abstract
Australia has become the first country to approve the use of psychedelics, namely MDMA and psilocybin, for clinical treatment of post-traumatic str...
Higher Consciousness
Science Translational Medicine – February 22, 2012
Summary
Psilocybin, a potent hallucinogen, profoundly alters consciousness by uncoupling key brain activity, offering a compelling new direction for Medicine. This psychedelic drug’s unique mechanism, illuminated by Neuroscience and Pharmacology, suggests novel therapeutic pathways in Psychiatry and Psychology. Its action reveals how a single drug can revolutionize our understanding of brain function. Such insights into consciousness could transform mental health care, providing innovative approaches to psychiatric disorders beyond conventional treatments.
Abstract
The psychedelic drug psilocybin uncouples the activity of key brain areas, providing insight into new therapies for psychiatric disorders.
Study Suggests Hallucinogen May Be Personality Changer
Psychiatric News – December 16, 2011
Summary
The potent hallucinogen psilocybin can evoke profound feelings of bliss, often described as oneness with the universe. However, a critical question in Psychology and Psychedelics and Drug Studies is whether these experiences represent genuine mysticism or spiritual growth. This inquiry challenges traditional views in Religious Studies and Spiritual Practices, prompting psychotherapists and those interested in psychoanalysis to consider the authenticity of such drug-induced states. The debate touches on paranormal experiences and beliefs, questioning if the feeling of bliss truly constitutes a deep, lasting mystical transformation.
Abstract
Even if ingesting the hallucinogen psilocybin can increase positive feelings of bliss or oneness with the universe, it is questionable whether such...
HPLC Sample Prep and Extraction SOP v1.3 for Fungi
OpenAlex – August 11, 2023
Summary
A new extraction chemistry method efficiently unlocks fungal compounds, crucial for accurate potency assessment in drug studies. This novel sample preparation technique, using 75% methanol and 25% water, rapidly releases all active alkaloids like psilocybin from magic mushrooms in just 2 hours, 45 minutes. Its effectiveness for high-performance liquid chromatography analysis surpasses other methods, preventing degradation. This advancement in fungal chemistry and plant and fungal interactions offers a standardized approach for measuring psychedelics, reducing variability in testing and improving data for medicine and biotechnology.
Abstract
medicine, industry, and biotechnology. Fungi produce a wide range of bioactive compounds, such as alkaloids, antibiotics, antifungals, immunomodula...